CDKN1A and neoplasm: Nevertheless, a different picture is obtained when tumors are investigated not hours, but 4 to 6 weeks post-therapy: the persistence of highly p21CIP/WAF-1-expressing tumor cells 4 to 6 weeks after the completion of a neoadjuvant multimodal therapy is an adverse effect for survival [6].